Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Compound Found to Reverse Down Syndrome-Like Learning Deficits in Mice

By BiotechDaily International staff writers
Posted on 23 Sep 2013
Researchers have identified a compound that dramatically boosts memory and learning when administered to mice with a Down syndrome-like disorder on the day of their birth. They reported that the single-dose treatment appears to enable the cerebellum of the rodents’ brains to grow to a normal size.

The scientists cautioned that use of the compound, a small molecule known as a sonic hedgehog pathway agonist, has not been shown to be safe to try in individuals with Down syndrome, but say their research has potential for developing similar drug.

The study’s findings were published in the September 4, 2012, issue of the journal Science Translational Medicine. “Most people with Down syndrome have a cerebellum that’s about 60% of the normal size,” stated Roger Reeves, PhD, a professor in the McKusick-Nathans Institute of Genetic Medicine at the Johns Hopkins University School of Medicine (Baltimore, MD, USA). “We treated the Down syndrome-like mice with a compound we thought might normalize the cerebellum’s growth, and it worked beautifully. What we didn’t expect were the effects on learning and memory, which are generally controlled by the hippocampus, not the cerebellum.”

Dr. Reeves has spent his career studying Down syndrome, a disorder that occurs when people have three, instead of the typical two, copies of chromosome 21. As a result of this trisomy, individuals with Down syndrome have extra copies of the more than 300 genes housed on that chromosome, which leads to intellectual disabilities, distinctive facial features and sometimes heart problems and other health effects. Because the disorder involves so many genes, developing therapy for it is a daunting task, according to Dr. Reeves.

Dr. Reeves and his colleagues, for the current research used mice that were genetically engineered to have extra copies of about half of the genes found on human chromosome 21. The mice have many features similar to those of people with Down syndrome, including comparatively small cerebellums and difficulty learning and remembering how to navigate through a recognizable space. (In the case of the mice, this was evaluated by tracking how easily the animals located a platform while swimming in a so-called water maze.)

Based on earlier research on how Down syndrome affects brain development, the researchers tried supercharging a biochemical chain of events known as the sonic hedgehog pathway that stimulate growth and development. They used an agent—a sonic hedgehog pathway agonist—that could accomplish the feat. The compound was injected into the Down syndrome-like mice just once, on the day of birth, while their cerebellums were still developing. “We were able to completely normalize growth of the cerebellum through adulthood with that single injection,” Dr. Reeves noted.

However, the researcher went beyond measuring the cerebellums, also looking for changes in behavior. “Making the animals, synthesizing the compound and guessing the right dose were so difficult and time-consuming that we wanted to get as much data out of the experiment as we could,” Dr. Reeves said. The scientists assessed the treated mice against untreated Down syndrome-like mice and healthy mice in a host of ways, and found that the treated mice did just as well as the normal ones on the water maze test.

Dr. Reeves noted that additional studies are needed to learn why exactly the treatment works, because their study of specific cells in the hippocampus known to be involved in learning and affected by Down syndrome appeared unaffected by the sonic hedgehog agonist treatment. One idea is that the treatment improved learning by strengthening communication between the cerebellum and the hippocampus, he noted.

As for the agent’s potential to become a drug for human use, the difficulty, according to Dr. Reeves, is that changing an important biologic chain of events such as sonic hedgehog would in all probability have many unintended effects throughout the body, such as increasing the risk of cancer by triggering uncontrolled growth. But now that the investigators have seen the potential of this approach, they will look for more targeted ways to safely control the power of sonic hedgehog in the cerebellum. Even if his team succeeds in developing a clinically useful drug, however, Dr. Reeves warned that it would not represent a “cure” for the learning and memory-related effects of Down syndrome. “Down syndrome is very complex, and nobody thinks there’s going to be a silver bullet that normalizes cognition,” he concluded. “Multiple approaches will be needed.”

Related Links:

Johns Hopkins University School of Medicine



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.